Newsletter | November 20, 2025

11.20.25 -- Making The Right Choice: CMO Or CDMO?

SPONSOR

Live Event: How Digital Tools Are Accelerating Biopharma Development

Register today for this digital event led by Bioprocess Online’s chief editor, Tyler Menichiello, features industry experts who will share for an engaging panel discussion on how companies are deploying advanced technologies and tools to accelerate biopharmaceutical development. This event is free to attend thanks to Cytiva.

FOCUS ON OUTSOURCING

Are You Still Evaluating CMOs When You Really Need A CDMO?

Outsourcing adds capacity and specialized knowledge to your supply chain. But contractors come in several types. Here's how to pick the right one.

What Can You Do To Improve Your ADC's Chance Of Clinical Success?

Improving your ADC’s chance of clinical success requires an understanding of what potential obstacles lie ahead and what capabilities and expertise are necessary to overcome them.

The Quantum Future Of Biosensing

While practical quantum computing applications remain far away, quantum biosensing applications with real-world impact in areas like immunotherapy and diagnostics are near at hand.

Optimizing Charge And N-glycan Profiles For CHO-Derived Fusion Proteins

Discover how structured design-of-experiment approaches can optimize charge variants and glycosylation to enhance biologics quality and therapeutic performance.

Seizing The Opportunity Under EMA's Streamlined Guidelines

Take proactive steps now to reduce development costs, accelerate approval, and unlock new opportunities in the shifting biosimilar landscape.

Progressing A Cystic Fibrosis Treatment With A Strong Culture Match

Collaborate with an experienced CMO that combines transparency, expertise, and a shared commitment to help advance complex biologics from preclinical research to clinical success.

Expanding Opportunities For Inhaled Drug Delivery

Review the challenges and intricacies of effectively delivering drugs to the lung and the advantages of using nanoparticles and gentle particle processing techniques to enable delivery of sensitive drugs.

Quicker Development Using Cell Line Integration, End-To-End Support

Despite challenges with mammalian host cell line diversity, Lonza's mitigation strategies drive efficiency and reproducibility, maximizing cell growth and product quality.

Exploring An Integrated Solution For AAV Vector Clinical Production

Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.

Flexibility And Capability In Pre-Filled Syringes: The Future Of PFS

Outlined here are the inherent benefits of PFS and how they relate to the delivery of drugs, such as biologics and vaccines, how SARS-CoV-2 could be fueling an explosive increase in PFS demand, and how a partnership with a flexible CDMO is the key to success.

De-Risking FDA Abbreviated New Drug Application (ANDA) Submissions

BD Physioject for Tirzepatide supports FDA ANDA submissions with proven usability, low error rates, and a design validated to match the reference listed autoinjector.

ICP-MS And ICP-OES: Tools For Elemental Impurity Analysis

Leverage advanced elemental impurity testing methods to ensure the safety, compliance, and accuracy of your drug products throughout the manufacturing process.

OUTSOURCING SOLUTIONS

XS Technologies Microbial Platform For Protein Expression - Lonza

Resilience Capacity Update July 2025: Large Molecule Drug Substance - Resilience US, Inc.

Custom Solution Partner: Specialized Capabilities, Expert Execution - Greenfield Global

Leveraging Advanced Technology And Proven Expertise - Catalent

Deliver Potent Cell Therapies Faster And More Reliably - BlueWhale Bio

An Agile, Fully Integrated Continuous Processing Platform - FUJIFILM Biotechnologies

Lonza Capacity Update January 2025: Fill/Finish - Lonza

You Make The Discovery. We Help Make It Reality. - Avid Bioservices

Sterile Drug Product - Curia

Connect With Bioprocess Online: